DanDi Bioscience

https://www.nbnews.kr/news/articleView.html?idxno=71432

This post has been translated from the original article dated 05/17/2023.

HLB Science xxxselected health care technology research and development project
HLB Science was finally xxxselected as the operator of the "2023 1st Health and Medical Technology Research and Development Project" organized by the Ministry of Health and Welfare.

The health care technology research and development project is a system in which the Ministry of Health and Welfare xxxselects and supports major tasks of promising research and development institutions in order to leap into a global bio-health-oriented country and establish health security. HLB Science, which is developing a peptide-based multidrug-resistant Gram-negative bacteria (Superbacteria) treatment called DD-S052P, will receive 2.75 billion won in research funds over the next three years with the xxxselection of the operator.

DD-S052P is a low-toxic synthetic peptide technology that combines with endotoxin (LPS) to kill bacteria and neutralize endotoxin. Although the number of deaths in Korea due to sepsis exceeds 6,000 every year and the fatality rate reaches 50%, the development of new drugs is urgent because there is no properly developed treatment yet. HLB Science's new drug development technology has been consistently recognized for its excellence, including being xxxselected as "Health and Medical R&D Excellence" by the Ministry of Health and Welfare in January.

HLB Science is currently undergoing phase 1 clinical trials in France to develop antibiotics for the treatment of sepsis and super bacteria. The Ministry of Health and Welfare plans to support the approval of the phase 2 clinical trial plan (IND) over the next three years so that global-level sepsis treatments can be developed. The project will be led by Yoon Young-kyung, a professor of medicine at Korea University who is an infectious medicine specialist, and HLB Science will participate as a joint research institute.

"DD-S052P, our new drug, is an innovative new drug with high potential that effectively prevents and treats sepsis and complications by neutralizing not only causative bacteria but also endotoxins," said Yoon Jong-sun, CEO of HLB Science. "As phase 1 is currently cruising, it is expected that phase 2 clinical trials will be approved without difficulty within three years. We plan to expand phase 2 to the United States and Europe and strengthen cooperation with global companies such as technology exports."

In addition to sepsis, HLB Science is developing an Alzheimer's treatment drug "DD-A279," a dementia diagnostic kit, and an endotoxin detection diagnostic device.

출처 : NBN NEWS(https://www.nbnews.kr)